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Background: For the last decade continuous efforts have been made to translate regenerative cell therapy
protocols in the cardiovascular field from ‘bench to bedside’. Successful clinical introduction, supporting safety, and
feasibility of this new therapeutic approach, led to the initiation of the German, Phase III, multicenter trial - termed
the PERFECT trial (ClinicalTrials.gov Identifier: NCT00950274), in order to evaluate the efficacy of surgical cardiac
cell therapy on left ventricular function.
Methods/Design: The PERFECT trial has been designed as a prospective, randomized, double-blind, placebo
controlled, multicenter trial, analyzing the effect of intramyocardial CD 133+ bone marrow stem cell injection in
combination with coronary artery bypass grafting on postoperative left ventricular function. The trial includes
patients aged between 18 and 79 years presenting with a coronary disease with indication for surgical
revascularization and reduced global left ventricular ejection fraction as assessed by cardiac magnet resonance
imaging. The included patients are treated in the chronic phase of ischemic cardiomyopathy after previous
myocardial infarction.
Discussion: Patients undergoing coronary artery bypass grafting in combination with intramyocardial CD133+ cell
injection will have a higher LV ejection fraction than patient who undergo CABG alone, measured 6 months after
the operation.
Trial registration: ClinicalTrials.gov Identifier: NCT00950274
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Ten years ago, after promising preclinical results [1,2],
cardiac stem cell application for regenerative purposes
was introduced in the fields of interventional cardiology
[3] and cardiac surgery [4] for the treatment of acute
myocardial infarction and chronic ischemic heart dis-
ease. Since intrinsic myocardial regeneration takes places* Correspondence: peter.donndorf@med.uni-rostock.de
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reproduction in any medium, provided the orbut is reduced during a normal life span [5], it is con-
ceivable that, in addition to revascularization proce-
dures, elderly patients in particular, forming the vast
majority of cardiologic and cardio-surgical patients,
might profit from attempts aimed at stimulating these
regenerative processes.
In our own group the capability of human CD133+
stem cells to restore cardiac function after myocardial
cryoinjury was tested utilizing immunodeficient mouse
models. Compared to CD133+ progenitor cells from the
cord blood, CD133+ cells derived from the bone marrow
were found to have beneficial effects on both post-injuryral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ility [6]. Moreover, by tracking of human DNA, the per-
sistence of progenitor cell progeny in the heart after
intramyocardial injection could be shown. As other
groups, we did not see direct myocardial differentiation
of these cells, although differentiation towards endothe-
lial phenotypes was clearly shown. Therefore it is ques-
tionable whether transdifferentiation of bone marrow
stem cells from hematopoietic linages to functional car-
diomyocytes (the hypothesis on which regenerative strat-
egies in the cardiovascular field were once based) truly
takes place. The reported functional improvement is
more likely due to the support of angiogenesis and arter-
iogenesis in the ischemic myocardium and the protec-
tion of cardiomyocytes from apoptotic cell death [7].
All these findings set the path for a clinical pilot trial
(Phase I) and subsequent controlled trial (Phase II)
studying the impact of intramyocardial injection of
CD133+ bone marrow stem cells in combination with
coronary artery bypass grafting (CABG) surgery in
chronic ischemic heart disease [8]. The clear and repro-
ducible beneficial effects of CD133+ cell therapy regard-
ing functional recovery of the ischemic myocardium and
the absence of any relevant side effects of intramyocar-
dial cell injection in the preclinical setting, provided the
basis for the shift from ‘bench to bedside’. After the first
reports of successful stem cell delivery to the injured
heart, the feasibility and safety of this new therapeutic
strategy could be proven for intracoronary [9] as well as
surgical intramyocardial [10] cell delivery, thereby focus-
ing on the treatment of ischemic heart disease. Over
1,000 patients with either recent myocardial infarction
or chronic ischemic heart failure have been treated so
far by means of interventional cardiology and cardiac
surgery [11].
However, the clinical efficacy of cardiac stem cell ap-
plication remains an open question even today. In order
to answer this question in terms of surgical stem cell
therapy, a randomized, double-blind, placebo controlled,
Phase III multicenter clinical trial - PERFECT, Intramyo-
cardial TransPlantation of BonE MaRrow Stem CellsTable 1 Major patient inclusion and exclusion criteria for the
Patient inclusion criteria
Coronary artery disease with indication for CABG
and previous myocardial infarction
LVEF between 25% and 50% measured by cardiac MRI
Akinetic/hypokinetic/hibernating left ventricular areas
localized by cardiac stress MRI
Absence of any moderate to severe valvular heart disease
requiring concomitant valve replacement or reconstruction
Informed consent of the patient
Age between 18 and 79 years
CRP, c-reactive protein; LVEF, left ventricular ejection fraction; MRI, magnet resonanFor ImprovEment of Post-Infarct MyoCardial Regener-
aTion in Addition to CABG Surgery - was launched.
The following null-hypothesis will be tested: ‘Patients
undergoing CABG & CD133+ cell injection do not have
a different LV ejection fraction than patient who under-
going CABG alone, measured 6 months after the oper-
ation’. Currently, the PERFECT trial is recruiting
patients.
The PERFECT trial has been approved by both inde-
pendent local ethics committees as well as the Paul
Erlich Institute representing a competent federal author-
ity in accordance with German legal requirements. All
procedures will be performed in accordance with the
principles of Good Clinical Practice (GCP) and the Dec-
laration of Helsinki.
Methods/Design
Study design and clinical endpoints
The PERFECT trial (ClinicalTrials.gov Identifier:
NCT00950274) has been designed as a prospective, ran-
domized, double-blind, placebo controlled, multicenter
trial, applying GCP standards. It is aimed at addressing
the issues mentioned above by providing evidence for
the effects of cardiac stem cell therapy in combination
with CABG surgery on ventricular function as well as
patients’ clinical outcomes and quality of life. Patients
between 18 and 79 years presenting with a coronary dis-
ease with indication for CABG and reduced global left
ventricular ejection fraction (LVEF) as assessed by car-
diac magnet resonance imaging (MRI) are included. For
detailed trial inclusion and exclusion criteria see Table 1.
Every patient being referred to CABG and presenting
with echocardiographic reduced LVEF after myocardial
infarction is screened for possible trial inclusion. Patient
screening is performed by physicians as well as study
nurses and final decision on CABG indication is taken
by a cardiac surgeon. Pre- and postoperative LVEF as-
sessment by cardiac MRI is performed in one core lab
facility and analyzed by a radiologist. Final decision on
trial inclusion is made based on the preoperative MRI
result and after written inform consent has beenPERFECT trial (ClinicalTrials.gov Identifier: NCT00950274)
Exclusion criteria
Emergency operation
Acute myocardial infarction within last 2 weeks
Resuscitation in combination with ventricular
arrhythmias within the last 14 days before treatment
Active cancer, organ transplantation, end-stage renal disorder
Infection (CRP≥ 20 mg/L, temperature ≥38.5 °C)
Contraindication for MRI
ce imaging.
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time point zero.Primary endpoint
– Left ventricular ejection fraction at rest, measured
by MRI (time frame: 6 months)Secondary endpoints
– Change in LVEF as assessed by MRI and
echocardiography (time frame: preoperatively, early
postoperatively (discharge), and 6 months)
– Regional contractility in the area of interest (AOI)/
Change in left ventricular end systolic diameter
(LVESD), left ventricular end diastolic diameter
(LVEDD) as assessed by echocardiography (time
frame: preoperatively, early postoperatively
(discharge), 6 months)
– Physical exercise capacity determined by 6-min walk
test (time frame: preoperatively, early
postoperatively (discharge), 6 months)
– NYHA and CCS class (time frame: preoperatively,
early postoperatively (discharge), 6 months)
– MACE (cardiac death, myocardial infarction,
secondary intervention/reoperation, ventricular
arrhythmia) (time frame: 6 months)
– QoL (Quality of life)-score: Minnesota Living with
Heart Failure Questionnaire, SF36 Questionnaire,
EQ-5D Questionnaire (time frame: preoperatively,
3 months, 6 months)
The following null hypothesis will be tested: ‘Patients
undergoing CABG & CD133+ cell injection do not have
a different LV ejection fraction than patient who under-
going CABG alone, measured 6 months after the oper-
ation’. Considerations for determining the sample size of
the primary efficacy parameter LVEP at 6 months post-
operatively, measured by MRI at rest, were carried out
on the basis of the results of a previous efficacy pilot
trial. The stratification of the primary analysis by center
is neglected in the sample size calculation. Instead of the
analysis of covariance (ANCOVA) to be used in the pri-
mary analysis, the two-sample t test scenario with equal
variances is considered.
Sample size determination was done under the as-
sumption of a two-sided type I error (α) at 5% and a type
II error (β) at 10% (that is, a power at 90%). The scenario
of a difference of about 4 to 5 is considered as a clinical
relevant difference. With a difference of 4.5 and a stand-
ard deviation of 7.5, at least n= 60 patients per group
are necessary and with an additional 15% drop-out rate
a total of at least 142 patients will be randomized.Patients will be randomized in a 1:1 ratio to undergo
CABG surgery in conjunction with either intramyocar-
dial injection of autologous CD133-enriched bone mar-
row cells or placebo. The randomization procedure is
stratified by study site and as randomization procedure
the permuted block design within strata is used. The
study treatment is randomly assigned in advance accord-
ing to the randomization list held and stored by a Bio-
statistician and using sealed envelopes provided to the
bone-marrow isolation laboratory. According to the in-
formation randomization is to be carried out and
CD133+ cell isolation product or placebo will be pro-
duced for the current patient.
Concealment is realized in a way that only members of
the team of the bone-marrow isolation laboratory will
have access to the randomization code. All members
have signed an agreement, stating that the randomization
code will be kept confidential and no person outside
members of the team of bone-marrow isolation labora-
tory will have access to the code.
Cell preparation
Isolation of CD133+ stem cells from the aspirated bone
marrow before CABG surgery is performed for all study
sites in one core lab facility under good manufacturing
practice (GMP) conditions using the CliniMACS CD133
System (Miltenyi Biotec GmbH, Bergisch Gladbach, Ger-
many). Random allocation will be performed in the cell
production facility, so that neither the patient nor the
surgeon nor any of the personnel involved in follow-up
examinations will know whether the cell product or pla-
cebo was administered.
A total of 0.5 to 5 × 106 CD133+ cells are prepared for
injection. The numerical difference to the doses used in
Phase I and II studies are due to different counting
methods.
Surgical stem cell injection during CABG
Intraoperative injections are performed into the target
regions after completion of the distal graft anastomoses
just before release of the aortic cross-clamp, utilizing
standardized 1 mL syringes. CD 133+ cells are suspended
in 5 mL physiological saline containing 10% autologous
serum. In control patients, equivalent placebo injections
containing physiological saline and 10% autologous
serum are performed. To visualize the target areas for
cell injections appointed by preoperative MRI analysis, a
segmental map of the left ventricular myocardium is
brought to the operating theater and targeted myocardial
regions are marked for optimal orientation of the sur-
geon. Moreover this kind of documentation allows exact
analysis of segmental changes in ventricular function
during follow-up in the context of cell injection target
areas.
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The trial will be conducted in several study sites. There-
fore centers will be considered as possible prognostic
factor influencing the outcome.
With regard to possible baseline and study site effects,
the two-sided hypothesis for the continuous primary ef-
ficacy variable LVEF at 6 months postoperatively will be
assessed using analysis of covariance (ANCOVA) adjust-
ing for baseline LVEF and study sites.
Secondary efficacy variables will be analyzed in a
strictly explorative way. If P values are computed, no ad-
justment for multiple testing will be made and they will
be interpreted in the exploratory sense. Similarly, confi-
dence intervals computed will be interpreted as interval
estimates for presence or absence of effects in the study
data.
In order to check differences between the treatment
groups for particular secondary endpoints (death, myo-
cardial infarction, need of reintervention) an unadjusted
survival analysis with Kaplan-Meier estimations will be
performed using the logrank test.
Two different sets of patients will be defined to per-
form analyses. A ‘Full Analysis Set’ (FAS) following the
principle of intent-to-treat (ITT) will include every pa-
tient as randomized and compare the patients according
to the group to which they were randomly allocated, re-
gardless of patients’ compliance, or withdrawal from the
study. It is the most cautious approach and so minimizes
type 1 error, helps preserve prognostic balance in the
study arms and allows for the greatest generalizability.
Secondly, an analysis of all per protocol treated
patients will be performed. The ‘Per Protocol Set’ (PPS)
sample will consist of all subjects from the FAS group
without any major protocol violation.
First and foremost, confirmatory analyses on primary
efficacy variable will be performed on the FAS patients
but a secondary analysis will also be performed based
upon the PPS, to assess the sensitivity of the analysis to
the choice of analysis population. The ITT analysis will
be considered as the primary one.
The safety population will comprise all patients ran-
domized into the study, in which each patient’s treat-
ment is as taken on the study. Safety evaluations will
be performed on the safety population. Adverse events
and serious adverse events will be listed summed by
occurrence, severity, outcome, and causal relationship
to treatment and will be descriptively compared be-
tween the two treatment groups using Fishers exact
test.
All statistical tests will be conducted using a two-sided
test with α= 0.05.
The statistical analysis of study results will be per-
formed according to the CPMP guidelines for ‘Biostatis-
tical methodology in clinical trials in applications formarketing authorizations for medical products’ and the
ICH guideline ‘Statistical principles for clinical trials’.
Discussion
The PERFECT trial, representing the first Phase III trial
for evaluation of intramyocardial bone marrow stem cell
therapy during CABG surgery, was initiated in 2009.
Based on solid preclinical evidence gained from preclin-
ical results demonstrating the capability of bone marrow
stem cells to partially restore cardiac function after is-
chemic damage in animal models and clinical results
from Phase I and II trials an evidence based RCT (ran-
domized controlled trial) is mandatory to make a step
forward in evaluating cardiac cell therapy as an relevant
therapeutic tool. However, if the Phase III trial results
support cardiac cell therapy as an effective therapeutic
option in chronic ischemic heart disease, further efforts
will most likely need to be taken to answer questions
regarding the exact mechanisms of stem cell migration,
differentiation and myocardial regeneration, in order to
optimize cell therapy protocols. Additionally the optimal
time point of cell application is still unclear. The current
concept for optimal timing of cardiac cell therapy after
ischemic myocardial injury is characterized by a ‘window
of opportunity’ representing a time point with the in-
flammatory response, the healing and the scarring
balanced in a most favorable way for the requirements
of homing, survival, and differentiation of therapeutically
applied stem cells. Currently, this time point seems to be
within the first month after myocardial infarction for the
treatment with bone marrow stem cells [12]. But the
clinical evidence regarding the optimal time point is
sparse, especially concerning the setting of chronic is-
chemic heart disease. For the PERFECT trial a minimal
time frame of 2 weeks between the underlying myocar-
dial infarction and cell therapy is required. This provides
acceptable tissue conditions for bypass surgery and the
primary inflammatory response is likely to have passed.
Only by a combined approach consisting of both, re-
search in the lab and consequent clinical translation, can
stem cell therapy become a truly standardized, thera-
peutic ‘tool’ in the field of regenerative medicine. There-
fore, and in addition to the clinical endpoints addressed,
intensive applied basic research is carried out concomi-
tantly to the PERFECT trial. Isolated CD133+ stem cells
from the patient’s bone marrow are characterized by
fluorescence activated cell sorting (FACS) analysis and
subpopulations are described for further classification
and standardization of the cell product. Vitality and pro-
liferation assays are performed and angiogenic potency
is assessed utilizing CFU-EC (colony forming unit-
endothelial cell) analysis in order to verify the regenera-
tive capacity of CD133+ cells. To learn more about the
possible intrinsic regenerative response mechanisms to
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analyzed at different points in time in the perioperative
course for markers of angiogenesis (VEGF, FGF), inflam-
matory response (IL-6, IL-8, TNF-α), endothelial activa-
tion (sE-selectin), and heart failure (myoglobin).
Additionally, perioperative mobilization of certain stem
cell sub-populations, like endothelial progenitor cells, is
assessed. In this way the PERFECT trial, besides provid-
ing evidence regarding the impact of surgical stem cell
therapy on patients’ functional and clinical outcome,
helps to further standardize the GMP produced, autolo-
gous cell product and to answer questions raised by the
basic research.
Furthermore, the authors believe that exact, critical,
and standardized pre-procedural evaluation of left ven-
tricular function as well as examination of regional myo-
cardial viability, preferably by cardiac MRI, form another
key issue for reaching possible therapeutic efficacy by
means of cardiac cell therapy. However, novel imaging
modalities like speckle tracking by two-dimensional
strain echocardiography might offer useful additional
tools for planning and evaluation of cardiac cell therapy




CABG: Coronary Artery Bypass Grafting; CCS: Canadian Cardiovascular Society;
CD: Cluster of Differentiation; CFU-EC: Colony forming Unit- Endothelial Cell;
GCP: Good Clinical Practice; MACE: Major Adverse Cardiovascular Event;
MRI: Magnet Resonance Imaging; NYHA: New York Heart Association;
LVEF: Left Ventricular Ejection Fraction; LVEDD: Left Ventricular End Diastolic
Diameter; LVESD: Left Ventricular End Systolic Diameter; QoL: Ouality of Life.
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